Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943583661> ?p ?o ?g. }
- W2943583661 endingPage "612" @default.
- W2943583661 startingPage "612" @default.
- W2943583661 abstract "Preclinical works have suggested cytotoxic chemotherapies may increase the number of cancer stem cells (CSC) whereas angiogenesis inhibition may decrease CSC proliferation. We developed a proof of concept clinical trial to explore bevacizumab activity on breast CSC. Breast cancer patients requiring preoperative chemotherapy were included in this open-label, randomized, prospective, multicenter phase II trial. All received FEC-docetaxel combination, and patients randomized in the experimental arm received concomitant bevacizumab. The primary endpoint was to describe ALDH1 (Aldehyde dehydrogenase 1) positive tumor cells rate before treatment and after the fourth cycle. Secondary objectives included safety, pathological complete response (pCR) rate, disease-free survival (DFS), relapse-free survival (RFS), and overall survival (OS). Seventy-five patients were included. ALDH1+ cells rate increase was below the predefined 5% threshold in both arms for the 32 patients with two time points available. Grade 3 or 4 adverse events rates were similar in both arms. A non-significant increase in pCR was observed in the bevacizumab arm (42.6% vs. 18.2%, p = 0.06), but survival was not improved (OS: p = 0.89; DFS: p = 0.45; and RFS: p = 0.68). The increase of ALDH1+ tumor cells rate after bevacizumab-based chemotherapy was less than 5%. However, as similar results were observed with chemotherapy alone, bevacizumab impact on breast CSC cells cannot be confirmed." @default.
- W2943583661 created "2019-05-09" @default.
- W2943583661 creator A5003470485 @default.
- W2943583661 creator A5006642161 @default.
- W2943583661 creator A5009364522 @default.
- W2943583661 creator A5011899504 @default.
- W2943583661 creator A5011917700 @default.
- W2943583661 creator A5015202957 @default.
- W2943583661 creator A5020758672 @default.
- W2943583661 creator A5031014006 @default.
- W2943583661 creator A5051839713 @default.
- W2943583661 creator A5065530531 @default.
- W2943583661 creator A5082444951 @default.
- W2943583661 creator A5084232219 @default.
- W2943583661 creator A5091721810 @default.
- W2943583661 date "2019-05-06" @default.
- W2943583661 modified "2023-10-18" @default.
- W2943583661 title "Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer" @default.
- W2943583661 cites W12086493 @default.
- W2943583661 cites W1949597673 @default.
- W2943583661 cites W1953884850 @default.
- W2943583661 cites W1958877028 @default.
- W2943583661 cites W1965124339 @default.
- W2943583661 cites W1968449590 @default.
- W2943583661 cites W1985712533 @default.
- W2943583661 cites W1987326983 @default.
- W2943583661 cites W1993780950 @default.
- W2943583661 cites W1994915831 @default.
- W2943583661 cites W2003311516 @default.
- W2943583661 cites W2008023699 @default.
- W2943583661 cites W2012619882 @default.
- W2943583661 cites W2014862104 @default.
- W2943583661 cites W2018669222 @default.
- W2943583661 cites W2023316892 @default.
- W2943583661 cites W2025021524 @default.
- W2943583661 cites W2035375527 @default.
- W2943583661 cites W2037761545 @default.
- W2943583661 cites W2044905529 @default.
- W2943583661 cites W2054979979 @default.
- W2943583661 cites W2075894019 @default.
- W2943583661 cites W2087179076 @default.
- W2943583661 cites W2088223306 @default.
- W2943583661 cites W2090032922 @default.
- W2943583661 cites W2098400442 @default.
- W2943583661 cites W2100756525 @default.
- W2943583661 cites W2102306754 @default.
- W2943583661 cites W2105504936 @default.
- W2943583661 cites W2117188579 @default.
- W2943583661 cites W2117692326 @default.
- W2943583661 cites W2122574381 @default.
- W2943583661 cites W2126275851 @default.
- W2943583661 cites W2127395702 @default.
- W2943583661 cites W2134140348 @default.
- W2943583661 cites W2140654333 @default.
- W2943583661 cites W2145835533 @default.
- W2943583661 cites W2147415463 @default.
- W2943583661 cites W2148103659 @default.
- W2943583661 cites W2151879335 @default.
- W2943583661 cites W2152387543 @default.
- W2943583661 cites W2153556154 @default.
- W2943583661 cites W2158627893 @default.
- W2943583661 cites W2159640574 @default.
- W2943583661 cites W2162760540 @default.
- W2943583661 cites W2164774797 @default.
- W2943583661 cites W2165286055 @default.
- W2943583661 cites W2167224460 @default.
- W2943583661 cites W2168414172 @default.
- W2943583661 cites W2170193835 @default.
- W2943583661 cites W2170928115 @default.
- W2943583661 cites W2171658624 @default.
- W2943583661 cites W2171958606 @default.
- W2943583661 cites W2245071643 @default.
- W2943583661 cites W2311739996 @default.
- W2943583661 cites W2323216105 @default.
- W2943583661 cites W2379981061 @default.
- W2943583661 cites W2389239223 @default.
- W2943583661 cites W2410989399 @default.
- W2943583661 cites W2533763458 @default.
- W2943583661 cites W2561439167 @default.
- W2943583661 cites W2741933352 @default.
- W2943583661 cites W2767470081 @default.
- W2943583661 cites W2781512217 @default.
- W2943583661 cites W2915478882 @default.
- W2943583661 cites W901978 @default.
- W2943583661 doi "https://doi.org/10.3390/jcm8050612" @default.
- W2943583661 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6572380" @default.
- W2943583661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31064127" @default.
- W2943583661 hasPublicationYear "2019" @default.
- W2943583661 type Work @default.
- W2943583661 sameAs 2943583661 @default.
- W2943583661 citedByCount "5" @default.
- W2943583661 countsByYear W29435836612021 @default.
- W2943583661 countsByYear W29435836612022 @default.
- W2943583661 countsByYear W29435836612023 @default.
- W2943583661 crossrefType "journal-article" @default.
- W2943583661 hasAuthorship W2943583661A5003470485 @default.
- W2943583661 hasAuthorship W2943583661A5006642161 @default.
- W2943583661 hasAuthorship W2943583661A5009364522 @default.